Conducted a regulatory risk-based audit for a Chinese pharmaceutical company

For a Chinese pharmaceutical company, lawyers of the practice conducted an audit of regulatory risks associated with products that were imported into Russia. The tasks before our lawyers included: assessing historical and potential regulatory and commercial risks as well as the risks of complaints from consumers and also issuing recommendations for how such risks can be mitigated.

As a result, the client was made aware of the pertinent risks associated with its products, including with regard to import duties, lawsuits from consumers and so on. The legal memo the client received was used to prepare the company for an IPO.

Office:  

Back to the list

13.03.2026
A Partner from Pepeliaev Group Has Been Appointed to the Panel of Arbitrators of the Hainan International Arbitration Court (HIAC)
Read more
03.03.2026
Pepeliaev Group Has Announced the Appointment of New Counsel
Read more
26.02.2026
Experts from Pepeliaev Group Have Achieved Outstanding Results in the Individual Pravo-300 Ranking for 2025
Read more